# KEYNOTE-042 (NCT02220894)

> Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: first-line PD-L1-positive advanced or metastatic non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02220894
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: pembrolizumab; carboplatin; paclitaxel; pemetrexed
- Enrollment: 1274
- Primary outcome: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%
- Primary outcome: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%
- Primary outcome: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%

## Indexed commentary on KEYNOTE-042 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 30
- Podcasts: 19
- YouTube: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-042-nct02220894

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02220894", "email": "<work email>"}; the inbox owner confirms by the emailed link.